Report Overview
Immunotherapy is treatment that uses a certain part of a person�s immune system to fight diseases which is done by stimulating one�s own immune system to work harder to attack cancer cells or by giving immune system components, such as man-made immune system proteins. Immunotherapy includes treatments that work in different ways. Some boost the body�s immune system in a very general way and others help train the immune system to attack cancer cells specifically.
The global Immuno-oncology Drugs market size was estimated at USD 17500 million in 2023 and is projected to reach USD 70798.43 million by 2032, exhibiting a CAGR of 16.80% during the forecast period.
North America Immuno-oncology Drugs market size was estimated at USD 5967.84 million in 2023, at a CAGR of 14.40% during the forecast period of 2025 through 2032.
This report provides a deep insight into the global Immuno-oncology Drugs market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, SWOT analysis, value chain analysis, etc.
The analysis helps the reader to shape the competition within the industries and strategies for the competitive environment to enhance the potential profit. Furthermore, it provides a simple framework for evaluating and accessing the position of the business organization. The report structure also focuses on the competitive landscape of the Global Immuno-oncology Drugs Market, this report introduces in detail the market share, market performance, product situation, operation situation, etc. of the main players, which helps the readers in the industry to identify the main competitors and deeply understand the competition pattern of the market.
In a word, this report is a must-read for industry players, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the Immuno-oncology Drugs market in any manner.
Global Immuno-oncology Drugs Market: Market Segmentation Analysis
The research report includes specific segments by region (country), manufacturers, Type, and Application. Market segmentation creates subsets of a market based on product type, end-user or application, Geographic, and other factors. By understanding the market segments, the decision-maker can leverage this targeting in the product, sales, and marketing strategies. Market segments can power your product development cycles by informing how you create product offerings for different segments.
Key Company
Amgen
Inc
AstraZeneca
Plc
Bristol-Myers Squibb
Celgene Corporation
Eli Lilly and Company
Merck & Co.
Hoffmann-La Roche AG
Johnson & Johnson
Novartis International AG
AbbVie
Inc.
Pfizer Inc.
Sanofi S.A.
EMD Serono
Inc.
Gilead Sciences Inc.
Prometheus Therapeutics & Diagnostics
Aduro BioTech
Galena Biopharma
Bavarian Nordic
Celldex Therapeutics
ImmunoCellular Therapeutics
Incyte
Dendreon Corporation
Agilent Technologies Inc.
Agenus Inc.
Enzo Biochem
Inc.
Lonza Group
Bio-Rad Laboratories
Inc.
Avantor
Inc.
Spring Bank Pharmaceuticals
Inc.
Ferring Pharmaceuticals
Market Segmentation (by Type)
Immune Checkpoint Inhibitors
Immune System Modulators
Cancer Vaccines
Oncolytic Virus
Others
Market Segmentation (by Application)
Hospitals
Clinics
Ambulatory Surgical Centers
Geographic Segmentation
� North America (USA, Canada, Mexico)
� Europe (Germany, UK, France, Russia, Italy, Rest of Europe)
� Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific)
� South America (Brazil, Argentina, Columbia, Rest of South America)
� The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA)
Key Benefits of This Market Research:
� Industry drivers, restraints, and opportunities covered in the study
� Neutral perspective on the market performance
� Recent industry trends and developments
� Competitive landscape & strategies of key players
� Potential & niche segments and regions exhibiting promising growth covered
� Historical, current, and projected market size, in terms of value
� In-depth analysis of the Immuno-oncology Drugs Market
� Overview of the regional outlook of the Immuno-oncology Drugs Market:
Key Reasons to Buy this Report:
� Access to date statistics compiled by our researchers. These provide you with historical and forecast data, which is analyzed to tell you why your market is set to change
� This enables you to anticipate market changes to remain ahead of your competitors
� You will be able to copy data from the Excel spreadsheet straight into your marketing plans, business presentations, or other strategic documents
� The concise analysis, clear graph, and table format will enable you to pinpoint the information you require quickly
� Provision of market value data for each segment and sub-segment
� Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market
� Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region
� Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled
� Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players
� The current as well as the future market outlook of the industry concerning recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions
� Includes in-depth analysis of the market from various perspectives through Porter�s five forces analysis
� Provides insight into the market through Value Chain
� Market dynamics scenario, along with growth opportunities of the market in the years to come
� 6-month post-sales analyst support
Customization of the Report
In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.
Chapter Outline
Chapter 1 mainly introduces the statistical scope of the report, market division standards, and market research methods.
Chapter 2 is an executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the Immuno-oncology Drugs Market and its likely evolution in the short to mid-term, and long term.
Chapter 3 makes a detailed analysis of the market's competitive landscape of the market and provides the market share, capacity, output, price, latest development plan, merger, and acquisition information of the main manufacturers in the market.
Chapter 4 is the analysis of the whole market industrial chain, including the upstream and downstream of the industry, as well as Porter's five forces analysis.
Chapter 5 introduces the latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 6 provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 7 provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 8 provides a quantitative analysis of the market size and development potential of each region from the consumer side and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 9 shares the main producing countries of Immuno-oncology Drugs, their output value, profit level, regional supply, production capacity layout, etc. from the supply side.
Chapter 10 introduces the basic situation of the main companies in the market in detail, including product sales revenue, sales volume, price, gross profit margin, market share, product introduction, recent development, etc.
Chapter 11 provides a quantitative analysis of the market size and development potential of each region during the forecast period.
Chapter 12 provides a quantitative analysis of the market size and development potential of each market segment during the forecast period.
Chapter 13 is the main points and conclusions of the report.
TABLE OF CONTENTS
Table of Contents
1 Research Methodology and Statistical Scope
1.1 Market Definition and Statistical Scope of Immuno-oncology Drugs
1.2 Key Market Segments
1.2.1 Immuno-oncology Drugs Segment by Type
1.2.2 Immuno-oncology Drugs Segment by Application
1.3 Methodology & Sources of Information
1.3.1 Research Methodology
1.3.2 Research Process
1.3.3 Market Breakdown and Data Triangulation
1.3.4 Base Year
1.3.5 Report Assumptions & Caveats
2 Immuno-oncology Drugs Market Overview
2.1 Global Market Overview
2.1.1 Global Immuno-oncology Drugs Market Size (M USD) Estimates and Forecasts (2019-2032)
2.1.2 Global Immuno-oncology Drugs Sales Estimates and Forecasts (2019-2032)
2.2 Market Segment Executive Summary
2.3 Global Market Size by Region
3 Immuno-oncology Drugs Market Competitive Landscape
3.1 Global Immuno-oncology Drugs Sales by Manufacturers (2019-2025)
3.2 Global Immuno-oncology Drugs Revenue Market Share by Manufacturers (2019-2025)
3.3 Immuno-oncology Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4 Global Immuno-oncology Drugs Average Price by Manufacturers (2019-2025)
3.5 Manufacturers Immuno-oncology Drugs Sales Sites, Area Served, Product Type
3.6 Immuno-oncology Drugs Market Competitive Situation and Trends
3.6.1 Immuno-oncology Drugs Market Concentration Rate
3.6.2 Global 5 and 10 Largest Immuno-oncology Drugs Players Market Share by Revenue
3.6.3 Mergers & Acquisitions, Expansion
4 Immuno-oncology Drugs Industry Chain Analysis
4.1 Immuno-oncology Drugs Industry Chain Analysis
4.2 Market Overview of Key Raw Materials
4.3 Midstream Market Analysis
4.4 Downstream Customer Analysis
5 The Development and Dynamics of Immuno-oncology Drugs Market
5.1 Key Development Trends
5.2 Driving Factors
5.3 Market Challenges
5.4 Market Restraints
5.5 Industry News
5.5.1 New Product Developments
5.5.2 Mergers & Acquisitions
5.5.3 Expansions
5.5.4 Collaboration/Supply Contracts
5.6 Industry Policies
6 Immuno-oncology Drugs Market Segmentation by Type
6.1 Evaluation Matrix of Segment Market Development Potential (Type)
6.2 Global Immuno-oncology Drugs Sales Market Share by Type (2019-2025)
6.3 Global Immuno-oncology Drugs Market Size Market Share by Type (2019-2025)
6.4 Global Immuno-oncology Drugs Price by Type (2019-2025)
7 Immuno-oncology Drugs Market Segmentation by Application
7.1 Evaluation Matrix of Segment Market Development Potential (Application)
7.2 Global Immuno-oncology Drugs Market Sales by Application (2019-2025)
7.3 Global Immuno-oncology Drugs Market Size (M USD) by Application (2019-2025)
7.4 Global Immuno-oncology Drugs Sales Growth Rate by Application (2019-2025)
8 Immuno-oncology Drugs Market Consumption by Region
8.1 Global Immuno-oncology Drugs Sales by Region
8.1.1 Global Immuno-oncology Drugs Sales by Region
8.1.2 Global Immuno-oncology Drugs Sales Market Share by Region
8.2 North America
8.2.1 North America Immuno-oncology Drugs Sales by Country
8.2.2 U.S.
8.2.3 Canada
8.2.4 Mexico
8.3 Europe
8.3.1 Europe Immuno-oncology Drugs Sales by Country
8.3.2 Germany
8.3.3 France
8.3.4 U.K.
8.3.5 Italy
8.3.6 Russia
8.4 Asia Pacific
8.4.1 Asia Pacific Immuno-oncology Drugs Sales by Region
8.4.2 China
8.4.3 Japan
8.4.4 South Korea
8.4.5 India
8.4.6 Southeast Asia
8.5 South America
8.5.1 South America Immuno-oncology Drugs Sales by Country
8.5.2 Brazil
8.5.3 Argentina
8.5.4 Columbia
8.6 Middle East and Africa
8.6.1 Middle East and Africa Immuno-oncology Drugs Sales by Region
8.6.2 Saudi Arabia
8.6.3 UAE
8.6.4 Egypt
8.6.5 Nigeria
8.6.6 South Africa
9 Immuno-oncology Drugs Market Production by Region
9.1 Global Production of Immuno-oncology Drugs by Region (2019-2025)
9.2 Global Immuno-oncology Drugs Revenue Market Share by Region (2019-2025)
9.3 Global Immuno-oncology Drugs Production, Revenue, Price and Gross Margin (2019-2025)
9.4 North America Immuno-oncology Drugs Production
9.4.1 North America Immuno-oncology Drugs Production Growth Rate (2019-2025)
9.4.2 North America Immuno-oncology Drugs Production, Revenue, Price and Gross Margin (2019-2025)
9.5 Europe Immuno-oncology Drugs Production
9.5.1 Europe Immuno-oncology Drugs Production Growth Rate (2019-2025)
9.5.2 Europe Immuno-oncology Drugs Production, Revenue, Price and Gross Margin (2019-2025)
9.6 Japan Immuno-oncology Drugs Production (2019-2025)
9.6.1 Japan Immuno-oncology Drugs Production Growth Rate (2019-2025)
9.6.2 Japan Immuno-oncology Drugs Production, Revenue, Price and Gross Margin (2019-2025)
9.7 China Immuno-oncology Drugs Production (2019-2025)
9.7.1 China Immuno-oncology Drugs Production Growth Rate (2019-2025)
9.7.2 China Immuno-oncology Drugs Production, Revenue, Price and Gross Margin (2019-2025)
10 Key Companies Profile
10.1 Amgen
10.1.1 Amgen Immuno-oncology Drugs Basic Information
10.1.2 Amgen Immuno-oncology Drugs Product Overview
10.1.3 Amgen Immuno-oncology Drugs Product Market Performance
10.1.4 Amgen Business Overview
10.1.5 Amgen Immuno-oncology Drugs SWOT Analysis
10.1.6 Amgen Recent Developments
10.2 Inc
10.2.1 Inc Immuno-oncology Drugs Basic Information
10.2.2 Inc Immuno-oncology Drugs Product Overview
10.2.3 Inc Immuno-oncology Drugs Product Market Performance
10.2.4 Inc Business Overview
10.2.5 Inc Immuno-oncology Drugs SWOT Analysis
10.2.6 Inc Recent Developments
10.3 AstraZeneca
10.3.1 AstraZeneca Immuno-oncology Drugs Basic Information
10.3.2 AstraZeneca Immuno-oncology Drugs Product Overview
10.3.3 AstraZeneca Immuno-oncology Drugs Product Market Performance
10.3.4 AstraZeneca Immuno-oncology Drugs SWOT Analysis
10.3.5 AstraZeneca Business Overview
10.3.6 AstraZeneca Recent Developments
10.4 Plc
10.4.1 Plc Immuno-oncology Drugs Basic Information
10.4.2 Plc Immuno-oncology Drugs Product Overview
10.4.3 Plc Immuno-oncology Drugs Product Market Performance
10.4.4 Plc Business Overview
10.4.5 Plc Recent Developments
10.5 Bristol-Myers Squibb
10.5.1 Bristol-Myers Squibb Immuno-oncology Drugs Basic Information
10.5.2 Bristol-Myers Squibb Immuno-oncology Drugs Product Overview
10.5.3 Bristol-Myers Squibb Immuno-oncology Drugs Product Market Performance
10.5.4 Bristol-Myers Squibb Business Overview
10.5.5 Bristol-Myers Squibb Recent Developments
10.6 Celgene Corporation
10.6.1 Celgene Corporation Immuno-oncology Drugs Basic Information
10.6.2 Celgene Corporation Immuno-oncology Drugs Product Overview
10.6.3 Celgene Corporation Immuno-oncology Drugs Product Market Performance
10.6.4 Celgene Corporation Business Overview
10.6.5 Celgene Corporation Recent Developments
10.7 Eli Lilly and Company
10.7.1 Eli Lilly and Company Immuno-oncology Drugs Basic Information
10.7.2 Eli Lilly and Company Immuno-oncology Drugs Product Overview
10.7.3 Eli Lilly and Company Immuno-oncology Drugs Product Market Performance
10.7.4 Eli Lilly and Company Business Overview
10.7.5 Eli Lilly and Company Recent Developments
10.8 Merck and Co.
10.8.1 Merck and Co. Immuno-oncology Drugs Basic Information
10.8.2 Merck and Co. Immuno-oncology Drugs Product Overview
10.8.3 Merck and Co. Immuno-oncology Drugs Product Market Performance
10.8.4 Merck and Co. Business Overview
10.8.5 Merck and Co. Recent Developments
10.9 Hoffmann-La Roche AG
10.9.1 Hoffmann-La Roche AG Immuno-oncology Drugs Basic Information
10.9.2 Hoffmann-La Roche AG Immuno-oncology Drugs Product Overview
10.9.3 Hoffmann-La Roche AG Immuno-oncology Drugs Product Market Performance
10.9.4 Hoffmann-La Roche AG Business Overview
10.9.5 Hoffmann-La Roche AG Recent Developments
10.10 Johnson and Johnson
10.10.1 Johnson and Johnson Immuno-oncology Drugs Basic Information
10.10.2 Johnson and Johnson Immuno-oncology Drugs Product Overview
10.10.3 Johnson and Johnson Immuno-oncology Drugs Product Market Performance
10.10.4 Johnson and Johnson Business Overview
10.10.5 Johnson and Johnson Recent Developments
10.11 Novartis International AG
10.11.1 Novartis International AG Immuno-oncology Drugs Basic Information
10.11.2 Novartis International AG Immuno-oncology Drugs Product Overview
10.11.3 Novartis International AG Immuno-oncology Drugs Product Market Performance
10.11.4 Novartis International AG Business Overview
10.11.5 Novartis International AG Recent Developments
10.12 AbbVie
10.12.1 AbbVie Immuno-oncology Drugs Basic Information
10.12.2 AbbVie Immuno-oncology Drugs Product Overview
10.12.3 AbbVie Immuno-oncology Drugs Product Market Performance
10.12.4 AbbVie Business Overview
10.12.5 AbbVie Recent Developments
10.13 Inc.
10.13.1 Inc. Immuno-oncology Drugs Basic Information
10.13.2 Inc. Immuno-oncology Drugs Product Overview
10.13.3 Inc. Immuno-oncology Drugs Product Market Performance
10.13.4 Inc. Business Overview
10.13.5 Inc. Recent Developments
10.14 Pfizer Inc.
10.14.1 Pfizer Inc. Immuno-oncology Drugs Basic Information
10.14.2 Pfizer Inc. Immuno-oncology Drugs Product Overview
10.14.3 Pfizer Inc. Immuno-oncology Drugs Product Market Performance
10.14.4 Pfizer Inc. Business Overview
10.14.5 Pfizer Inc. Recent Developments
10.15 Sanofi S.A.
10.15.1 Sanofi S.A. Immuno-oncology Drugs Basic Information
10.15.2 Sanofi S.A. Immuno-oncology Drugs Product Overview
10.15.3 Sanofi S.A. Immuno-oncology Drugs Product Market Performance
10.15.4 Sanofi S.A. Business Overview
10.15.5 Sanofi S.A. Recent Developments
10.16 EMD Serono
10.16.1 EMD Serono Immuno-oncology Drugs Basic Information
10.16.2 EMD Serono Immuno-oncology Drugs Product Overview
10.16.3 EMD Serono Immuno-oncology Drugs Product Market Performance
10.16.4 EMD Serono Business Overview
10.16.5 EMD Serono Recent Developments
10.17 Inc.
10.17.1 Inc. Immuno-oncology Drugs Basic Information
10.17.2 Inc. Immuno-oncology Drugs Product Overview
10.17.3 Inc. Immuno-oncology Drugs Product Market Performance
10.17.4 Inc. Business Overview
10.17.5 Inc. Recent Developments
10.18 Gilead Sciences Inc.
10.18.1 Gilead Sciences Inc. Immuno-oncology Drugs Basic Information
10.18.2 Gilead Sciences Inc. Immuno-oncology Drugs Product Overview
10.18.3 Gilead Sciences Inc. Immuno-oncology Drugs Product Market Performance
10.18.4 Gilead Sciences Inc. Business Overview
10.18.5 Gilead Sciences Inc. Recent Developments
10.19 Prometheus Therapeutics and Diagnostics
10.19.1 Prometheus Therapeutics and Diagnostics Immuno-oncology Drugs Basic Information
10.19.2 Prometheus Therapeutics and Diagnostics Immuno-oncology Drugs Product Overview
10.19.3 Prometheus Therapeutics and Diagnostics Immuno-oncology Drugs Product Market Performance
10.19.4 Prometheus Therapeutics and Diagnostics Business Overview
10.19.5 Prometheus Therapeutics and Diagnostics Recent Developments
10.20 Aduro BioTech
10.20.1 Aduro BioTech Immuno-oncology Drugs Basic Information
10.20.2 Aduro BioTech Immuno-oncology Drugs Product Overview
10.20.3 Aduro BioTech Immuno-oncology Drugs Product Market Performance
10.20.4 Aduro BioTech Business Overview
10.20.5 Aduro BioTech Recent Developments
10.21 Galena Biopharma
10.21.1 Galena Biopharma Immuno-oncology Drugs Basic Information
10.21.2 Galena Biopharma Immuno-oncology Drugs Product Overview
10.21.3 Galena Biopharma Immuno-oncology Drugs Product Market Performance
10.21.4 Galena Biopharma Business Overview
10.21.5 Galena Biopharma Recent Developments
10.22 Bavarian Nordic
10.22.1 Bavarian Nordic Immuno-oncology Drugs Basic Information
10.22.2 Bavarian Nordic Immuno-oncology Drugs Product Overview
10.22.3 Bavarian Nordic Immuno-oncology Drugs Product Market Performance
10.22.4 Bavarian Nordic Business Overview
10.22.5 Bavarian Nordic Recent Developments
10.23 Celldex Therapeutics
10.23.1 Celldex Therapeutics Immuno-oncology Drugs Basic Information
10.23.2 Celldex Therapeutics Immuno-oncology Drugs Product Overview
10.23.3 Celldex Therapeutics Immuno-oncology Drugs Product Market Performance
10.23.4 Celldex Therapeutics Business Overview
10.23.5 Celldex Therapeutics Recent Developments
10.24 ImmunoCellular Therapeutics
10.24.1 ImmunoCellular Therapeutics Immuno-oncology Drugs Basic Information
10.24.2 ImmunoCellular Therapeutics Immuno-oncology Drugs Product Overview
10.24.3 ImmunoCellular Therapeutics Immuno-oncology Drugs Product Market Performance
10.24.4 ImmunoCellular Therapeutics Business Overview
10.24.5 ImmunoCellular Therapeutics Recent Developments
10.25 Incyte
10.25.1 Incyte Immuno-oncology Drugs Basic Information
10.25.2 Incyte Immuno-oncology Drugs Product Overview
10.25.3 Incyte Immuno-oncology Drugs Product Market Performance
10.25.4 Incyte Business Overview
10.25.5 Incyte Recent Developments
10.26 Dendreon Corporation
10.26.1 Dendreon Corporation Immuno-oncology Drugs Basic Information
10.26.2 Dendreon Corporation Immuno-oncology Drugs Product Overview
10.26.3 Dendreon Corporation Immuno-oncology Drugs Product Market Performance
10.26.4 Dendreon Corporation Business Overview
10.26.5 Dendreon Corporation Recent Developments
10.27 Agilent Technologies Inc.
10.27.1 Agilent Technologies Inc. Immuno-oncology Drugs Basic Information
10.27.2 Agilent Technologies Inc. Immuno-oncology Drugs Product Overview
10.27.3 Agilent Technologies Inc. Immuno-oncology Drugs Product Market Performance
10.27.4 Agilent Technologies Inc. Business Overview
10.27.5 Agilent Technologies Inc. Recent Developments
10.28 Agenus Inc.
10.28.1 Agenus Inc. Immuno-oncology Drugs Basic Information
10.28.2 Agenus Inc. Immuno-oncology Drugs Product Overview
10.28.3 Agenus Inc. Immuno-oncology Drugs Product Market Performance
10.28.4 Agenus Inc. Business Overview
10.28.5 Agenus Inc. Recent Developments
10.29 Enzo Biochem
10.29.1 Enzo Biochem Immuno-oncology Drugs Basic Information
10.29.2 Enzo Biochem Immuno-oncology Drugs Product Overview
10.29.3 Enzo Biochem Immuno-oncology Drugs Product Market Performance
10.29.4 Enzo Biochem Business Overview
10.29.5 Enzo Biochem Recent Developments
10.30 Inc.
10.30.1 Inc. Immuno-oncology Drugs Basic Information
10.30.2 Inc. Immuno-oncology Drugs Product Overview
10.30.3 Inc. Immuno-oncology Drugs Product Market Performance
10.30.4 Inc. Business Overview
10.30.5 Inc. Recent Developments
11 Immuno-oncology Drugs Market Forecast by Region
11.1 Global Immuno-oncology Drugs Market Size Forecast
11.2 Global Immuno-oncology Drugs Market Forecast by Region
11.2.1 North America Market Size Forecast by Country
11.2.2 Europe Immuno-oncology Drugs Market Size Forecast by Country
11.2.3 Asia Pacific Immuno-oncology Drugs Market Size Forecast by Region
11.2.4 South America Immuno-oncology Drugs Market Size Forecast by Country
11.2.5 Middle East and Africa Forecasted Consumption of Immuno-oncology Drugs by Country
12 Forecast Market by Type and by Application (2025-2032)
12.1 Global Immuno-oncology Drugs Market Forecast by Type (2025-2032)
12.1.1 Global Forecasted Sales of Immuno-oncology Drugs by Type (2025-2032)
12.1.2 Global Immuno-oncology Drugs Market Size Forecast by Type (2025-2032)
12.1.3 Global Forecasted Price of Immuno-oncology Drugs by Type (2025-2032)
12.2 Global Immuno-oncology Drugs Market Forecast by Application (2025-2032)
12.2.1 Global Immuno-oncology Drugs Sales (K MT) Forecast by Application
12.2.2 Global Immuno-oncology Drugs Market Size (M USD) Forecast by Application (2025-2032)
13 Conclusion and Key Findings
LIST OF TABLES & FIGURES
List of Tables
Table 1. Introduction of the Type
Table 2. Introduction of the Application
Table 3. Market Size (M USD) Segment Executive Summary
Table 4. Immuno-oncology Drugs Market Size Comparison by Region (M USD)
Table 5. Global Immuno-oncology Drugs Sales (K MT) by Manufacturers (2019-2025)
Table 6. Global Immuno-oncology Drugs Sales Market Share by Manufacturers (2019-2025)
Table 7. Global Immuno-oncology Drugs Revenue (M USD) by Manufacturers (2019-2025)
Table 8. Global Immuno-oncology Drugs Revenue Share by Manufacturers (2019-2025)
Table 9. Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Immuno-oncology Drugs as of 2022)
Table 10. Global Market Immuno-oncology Drugs Average Price (USD/MT) of Key Manufacturers (2019-2025)
Table 11. Manufacturers Immuno-oncology Drugs Sales Sites and Area Served
Table 12. Manufacturers Immuno-oncology Drugs Product Type
Table 13. Global Immuno-oncology Drugs Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Mergers & Acquisitions, Expansion Plans
Table 15. Industry Chain Map of Immuno-oncology Drugs
Table 16. Market Overview of Key Raw Materials
Table 17. Midstream Market Analysis
Table 18. Downstream Customer Analysis
Table 19. Key Development Trends
Table 20. Driving Factors
Table 21. Immuno-oncology Drugs Market Challenges
Table 22. Global Immuno-oncology Drugs Sales by Type (K MT)
Table 23. Global Immuno-oncology Drugs Market Size by Type (M USD)
Table 24. Global Immuno-oncology Drugs Sales (K MT) by Type (2019-2025)
Table 25. Global Immuno-oncology Drugs Sales Market Share by Type (2019-2025)
Table 26. Global Immuno-oncology Drugs Market Size (M USD) by Type (2019-2025)
Table 27. Global Immuno-oncology Drugs Market Size Share by Type (2019-2025)
Table 28. Global Immuno-oncology Drugs Price (USD/MT) by Type (2019-2025)
Table 29. Global Immuno-oncology Drugs Sales (K MT) by Application
Table 30. Global Immuno-oncology Drugs Market Size by Application
Table 31. Global Immuno-oncology Drugs Sales by Application (2019-2025) & (K MT)
Table 32. Global Immuno-oncology Drugs Sales Market Share by Application (2019-2025)
Table 33. Global Immuno-oncology Drugs Sales by Application (2019-2025) & (M USD)
Table 34. Global Immuno-oncology Drugs Market Share by Application (2019-2025)
Table 35. Global Immuno-oncology Drugs Sales Growth Rate by Application (2019-2025)
Table 36. Global Immuno-oncology Drugs Sales by Region (2019-2025) & (K MT)
Table 37. Global Immuno-oncology Drugs Sales Market Share by Region (2019-2025)
Table 38. North America Immuno-oncology Drugs Sales by Country (2019-2025) & (K MT)
Table 39. Europe Immuno-oncology Drugs Sales by Country (2019-2025) & (K MT)
Table 40. Asia Pacific Immuno-oncology Drugs Sales by Region (2019-2025) & (K MT)
Table 41. South America Immuno-oncology Drugs Sales by Country (2019-2025) & (K MT)
Table 42. Middle East and Africa Immuno-oncology Drugs Sales by Region (2019-2025) & (K MT)
Table 43. Global Immuno-oncology Drugs Production (K MT) by Region (2019-2025)
Table 44. Global Immuno-oncology Drugs Revenue (US$ Million) by Region (2019-2025)
Table 45. Global Immuno-oncology Drugs Revenue Market Share by Region (2019-2025)
Table 46. Global Immuno-oncology Drugs Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2019-2025)
Table 47. North America Immuno-oncology Drugs Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2019-2025)
Table 48. Europe Immuno-oncology Drugs Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2019-2025)
Table 49. Japan Immuno-oncology Drugs Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2019-2025)
Table 50. China Immuno-oncology Drugs Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2019-2025)
Table 51. Amgen Immuno-oncology Drugs Basic Information
Table 52. Amgen Immuno-oncology Drugs Product Overview
Table 53. Amgen Immuno-oncology Drugs Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2025)
Table 54. Amgen Business Overview
Table 55. Amgen Immuno-oncology Drugs SWOT Analysis
Table 56. Amgen Recent Developments
Table 57. Inc Immuno-oncology Drugs Basic Information
Table 58. Inc Immuno-oncology Drugs Product Overview
Table 59. Inc Immuno-oncology Drugs Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2025)
Table 60. Inc Business Overview
Table 61. Inc Immuno-oncology Drugs SWOT Analysis
Table 62. Inc Recent Developments
Table 63. AstraZeneca Immuno-oncology Drugs Basic Information
Table 64. AstraZeneca Immuno-oncology Drugs Product Overview
Table 65. AstraZeneca Immuno-oncology Drugs Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2025)
Table 66. AstraZeneca Immuno-oncology Drugs SWOT Analysis
Table 67. AstraZeneca Business Overview
Table 68. AstraZeneca Recent Developments
Table 69. Plc Immuno-oncology Drugs Basic Information
Table 70. Plc Immuno-oncology Drugs Product Overview
Table 71. Plc Immuno-oncology Drugs Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2025)
Table 72. Plc Business Overview
Table 73. Plc Recent Developments
Table 74. Bristol-Myers Squibb Immuno-oncology Drugs Basic Information
Table 75. Bristol-Myers Squibb Immuno-oncology Drugs Product Overview
Table 76. Bristol-Myers Squibb Immuno-oncology Drugs Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2025)
Table 77. Bristol-Myers Squibb Business Overview
Table 78. Bristol-Myers Squibb Recent Developments
Table 79. Celgene Corporation Immuno-oncology Drugs Basic Information
Table 80. Celgene Corporation Immuno-oncology Drugs Product Overview
Table 81. Celgene Corporation Immuno-oncology Drugs Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2025)
Table 82. Celgene Corporation Business Overview
Table 83. Celgene Corporation Recent Developments
Table 84. Eli Lilly and Company Immuno-oncology Drugs Basic Information
Table 85. Eli Lilly and Company Immuno-oncology Drugs Product Overview
Table 86. Eli Lilly and Company Immuno-oncology Drugs Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2025)
Table 87. Eli Lilly and Company Business Overview
Table 88. Eli Lilly and Company Recent Developments
Table 89. Merck and Co. Immuno-oncology Drugs Basic Information
Table 90. Merck and Co. Immuno-oncology Drugs Product Overview
Table 91. Merck and Co. Immuno-oncology Drugs Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2025)
Table 92. Merck and Co. Business Overview
Table 93. Merck and Co. Recent Developments
Table 94. Hoffmann-La Roche AG Immuno-oncology Drugs Basic Information
Table 95. Hoffmann-La Roche AG Immuno-oncology Drugs Product Overview
Table 96. Hoffmann-La Roche AG Immuno-oncology Drugs Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2025)
Table 97. Hoffmann-La Roche AG Business Overview
Table 98. Hoffmann-La Roche AG Recent Developments
Table 99. Johnson and Johnson Immuno-oncology Drugs Basic Information
Table 100. Johnson and Johnson Immuno-oncology Drugs Product Overview
Table 101. Johnson and Johnson Immuno-oncology Drugs Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2025)
Table 102. Johnson and Johnson Business Overview
Table 103. Johnson and Johnson Recent Developments
Table 104. Novartis International AG Immuno-oncology Drugs Basic Information
Table 105. Novartis International AG Immuno-oncology Drugs Product Overview
Table 106. Novartis International AG Immuno-oncology Drugs Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2025)
Table 107. Novartis International AG Business Overview
Table 108. Novartis International AG Recent Developments
Table 109. AbbVie Immuno-oncology Drugs Basic Information
Table 110. AbbVie Immuno-oncology Drugs Product Overview
Table 111. AbbVie Immuno-oncology Drugs Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2025)
Table 112. AbbVie Business Overview
Table 113. AbbVie Recent Developments
Table 114. Inc. Immuno-oncology Drugs Basic Information
Table 115. Inc. Immuno-oncology Drugs Product Overview
Table 116. Inc. Immuno-oncology Drugs Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2025)
Table 117. Inc. Business Overview
Table 118. Inc. Recent Developments
Table 119. Pfizer Inc. Immuno-oncology Drugs Basic Information
Table 120. Pfizer Inc. Immuno-oncology Drugs Product Overview
Table 121. Pfizer Inc. Immuno-oncology Drugs Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2025)
Table 122. Pfizer Inc. Business Overview
Table 123. Pfizer Inc. Recent Developments
Table 124. Sanofi S.A. Immuno-oncology Drugs Basic Information
Table 125. Sanofi S.A. Immuno-oncology Drugs Product Overview
Table 126. Sanofi S.A. Immuno-oncology Drugs Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2025)
Table 127. Sanofi S.A. Business Overview
Table 128. Sanofi S.A. Recent Developments
Table 129. EMD Serono Immuno-oncology Drugs Basic Information
Table 130. EMD Serono Immuno-oncology Drugs Product Overview
Table 131. EMD Serono Immuno-oncology Drugs Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2025)
Table 132. EMD Serono Business Overview
Table 133. EMD Serono Recent Developments
Table 134. Inc. Immuno-oncology Drugs Basic Information
Table 135. Inc. Immuno-oncology Drugs Product Overview
Table 136. Inc. Immuno-oncology Drugs Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2025)
Table 137. Inc. Business Overview
Table 138. Inc. Recent Developments
Table 139. Gilead Sciences Inc. Immuno-oncology Drugs Basic Information
Table 140. Gilead Sciences Inc. Immuno-oncology Drugs Product Overview
Table 141. Gilead Sciences Inc. Immuno-oncology Drugs Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2025)
Table 142. Gilead Sciences Inc. Business Overview
Table 143. Gilead Sciences Inc. Recent Developments
Table 144. Prometheus Therapeutics and Diagnostics Immuno-oncology Drugs Basic Information
Table 145. Prometheus Therapeutics and Diagnostics Immuno-oncology Drugs Product Overview
Table 146. Prometheus Therapeutics and Diagnostics Immuno-oncology Drugs Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2025)
Table 147. Prometheus Therapeutics and Diagnostics Business Overview
Table 148. Prometheus Therapeutics and Diagnostics Recent Developments
Table 149. Aduro BioTech Immuno-oncology Drugs Basic Information
Table 150. Aduro BioTech Immuno-oncology Drugs Product Overview
Table 151. Aduro BioTech Immuno-oncology Drugs Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2025)
Table 152. Aduro BioTech Business Overview
Table 153. Aduro BioTech Recent Developments
Table 154. Galena Biopharma Immuno-oncology Drugs Basic Information
Table 155. Galena Biopharma Immuno-oncology Drugs Product Overview
Table 156. Galena Biopharma Immuno-oncology Drugs Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2025)
Table 157. Galena Biopharma Business Overview
Table 158. Galena Biopharma Recent Developments
Table 159. Bavarian Nordic Immuno-oncology Drugs Basic Information
Table 160. Bavarian Nordic Immuno-oncology Drugs Product Overview
Table 161. Bavarian Nordic Immuno-oncology Drugs Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2025)
Table 162. Bavarian Nordic Business Overview
Table 163. Bavarian Nordic Recent Developments
Table 164. Celldex Therapeutics Immuno-oncology Drugs Basic Information
Table 165. Celldex Therapeutics Immuno-oncology Drugs Product Overview
Table 166. Celldex Therapeutics Immuno-oncology Drugs Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2025)
Table 167. Celldex Therapeutics Business Overview
Table 168. Celldex Therapeutics Recent Developments
Table 169. ImmunoCellular Therapeutics Immuno-oncology Drugs Basic Information
Table 170. ImmunoCellular Therapeutics Immuno-oncology Drugs Product Overview
Table 171. ImmunoCellular Therapeutics Immuno-oncology Drugs Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2025)
Table 172. ImmunoCellular Therapeutics Business Overview
Table 173. ImmunoCellular Therapeutics Recent Developments
Table 174. Incyte Immuno-oncology Drugs Basic Information
Table 175. Incyte Immuno-oncology Drugs Product Overview
Table 176. Incyte Immuno-oncology Drugs Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2025)
Table 177. Incyte Business Overview
Table 178. Incyte Recent Developments
Table 179. Dendreon Corporation Immuno-oncology Drugs Basic Information
Table 180. Dendreon Corporation Immuno-oncology Drugs Product Overview
Table 181. Dendreon Corporation Immuno-oncology Drugs Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2025)
Table 182. Dendreon Corporation Business Overview
Table 183. Dendreon Corporation Recent Developments
Table 184. Agilent Technologies Inc. Immuno-oncology Drugs Basic Information
Table 185. Agilent Technologies Inc. Immuno-oncology Drugs Product Overview
Table 186. Agilent Technologies Inc. Immuno-oncology Drugs Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2025)
Table 187. Agilent Technologies Inc. Business Overview
Table 188. Agilent Technologies Inc. Recent Developments
Table 189. Agenus Inc. Immuno-oncology Drugs Basic Information
Table 190. Agenus Inc. Immuno-oncology Drugs Product Overview
Table 191. Agenus Inc. Immuno-oncology Drugs Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2025)
Table 192. Agenus Inc. Business Overview
Table 193. Agenus Inc. Recent Developments
Table 194. Enzo Biochem Immuno-oncology Drugs Basic Information
Table 195. Enzo Biochem Immuno-oncology Drugs Product Overview
Table 196. Enzo Biochem Immuno-oncology Drugs Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2025)
Table 197. Enzo Biochem Business Overview
Table 198. Enzo Biochem Recent Developments
Table 199. Inc. Immuno-oncology Drugs Basic Information
Table 200. Inc. Immuno-oncology Drugs Product Overview
Table 201. Inc. Immuno-oncology Drugs Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2025)
Table 202. Inc. Business Overview
Table 203. Inc. Recent Developments
Table 204. Global Immuno-oncology Drugs Sales Forecast by Region (2025-2032) & (K MT)
Table 205. Global Immuno-oncology Drugs Market Size Forecast by Region (2025-2032) & (M USD)
Table 206. North America Immuno-oncology Drugs Sales Forecast by Country (2025-2032) & (K MT)
Table 207. North America Immuno-oncology Drugs Market Size Forecast by Country (2025-2032) & (M USD)
Table 208. Europe Immuno-oncology Drugs Sales Forecast by Country (2025-2032) & (K MT)
Table 209. Europe Immuno-oncology Drugs Market Size Forecast by Country (2025-2032) & (M USD)
Table 210. Asia Pacific Immuno-oncology Drugs Sales Forecast by Region (2025-2032) & (K MT)
Table 211. Asia Pacific Immuno-oncology Drugs Market Size Forecast by Region (2025-2032) & (M USD)
Table 212. South America Immuno-oncology Drugs Sales Forecast by Country (2025-2032) & (K MT)
Table 213. South America Immuno-oncology Drugs Market Size Forecast by Country (2025-2032) & (M USD)
Table 214. Middle East and Africa Immuno-oncology Drugs Consumption Forecast by Country (2025-2032) & (Units)
Table 215. Middle East and Africa Immuno-oncology Drugs Market Size Forecast by Country (2025-2032) & (M USD)
Table 216. Global Immuno-oncology Drugs Sales Forecast by Type (2025-2032) & (K MT)
Table 217. Global Immuno-oncology Drugs Market Size Forecast by Type (2025-2032) & (M USD)
Table 218. Global Immuno-oncology Drugs Price Forecast by Type (2025-2032) & (USD/MT)
Table 219. Global Immuno-oncology Drugs Sales (K MT) Forecast by Application (2025-2032)
Table 220. Global Immuno-oncology Drugs Market Size Forecast by Application (2025-2032) & (M USD)
List of Figures
Figure 1. Product Picture of Immuno-oncology Drugs
Figure 2. Data Triangulation
Figure 3. Key Caveats
Figure 4. Global Immuno-oncology Drugs Market Size (M USD), 2019-2032
Figure 5. Global Immuno-oncology Drugs Market Size (M USD) (2019-2032)
Figure 6. Global Immuno-oncology Drugs Sales (K MT) & (2019-2032)
Figure 7. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 8. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 9. Evaluation Matrix of Regional Market Development Potential
Figure 10. Immuno-oncology Drugs Market Size by Country (M USD)
Figure 11. Immuno-oncology Drugs Sales Share by Manufacturers in 2023
Figure 12. Global Immuno-oncology Drugs Revenue Share by Manufacturers in 2023
Figure 13. Immuno-oncology Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2023
Figure 14. Global Market Immuno-oncology Drugs Average Price (USD/MT) of Key Manufacturers in 2023
Figure 15. The Global 5 and 10 Largest Players: Market Share by Immuno-oncology Drugs Revenue in 2023
Figure 16. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 17. Global Immuno-oncology Drugs Market Share by Type
Figure 18. Sales Market Share of Immuno-oncology Drugs by Type (2019-2025)
Figure 19. Sales Market Share of Immuno-oncology Drugs by Type in 2023
Figure 20. Market Size Share of Immuno-oncology Drugs by Type (2019-2025)
Figure 21. Market Size Market Share of Immuno-oncology Drugs by Type in 2023
Figure 22. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 23. Global Immuno-oncology Drugs Market Share by Application
Figure 24. Global Immuno-oncology Drugs Sales Market Share by Application (2019-2025)
Figure 25. Global Immuno-oncology Drugs Sales Market Share by Application in 2023
Figure 26. Global Immuno-oncology Drugs Market Share by Application (2019-2025)
Figure 27. Global Immuno-oncology Drugs Market Share by Application in 2023
Figure 28. Global Immuno-oncology Drugs Sales Growth Rate by Application (2019-2025)
Figure 29. Global Immuno-oncology Drugs Sales Market Share by Region (2019-2025)
Figure 30. North America Immuno-oncology Drugs Sales and Growth Rate (2019-2025) & (K MT)
Figure 31. North America Immuno-oncology Drugs Sales Market Share by Country in 2023
Figure 32. U.S. Immuno-oncology Drugs Sales and Growth Rate (2019-2025) & (K MT)
Figure 33. Canada Immuno-oncology Drugs Sales (K MT) and Growth Rate (2019-2025)
Figure 34. Mexico Immuno-oncology Drugs Sales (Units) and Growth Rate (2019-2025)
Figure 35. Europe Immuno-oncology Drugs Sales and Growth Rate (2019-2025) & (K MT)
Figure 36. Europe Immuno-oncology Drugs Sales Market Share by Country in 2023
Figure 37. Germany Immuno-oncology Drugs Sales and Growth Rate (2019-2025) & (K MT)
Figure 38. France Immuno-oncology Drugs Sales and Growth Rate (2019-2025) & (K MT)
Figure 39. U.K. Immuno-oncology Drugs Sales and Growth Rate (2019-2025) & (K MT)
Figure 40. Italy Immuno-oncology Drugs Sales and Growth Rate (2019-2025) & (K MT)
Figure 41. Russia Immuno-oncology Drugs Sales and Growth Rate (2019-2025) & (K MT)
Figure 42. Asia Pacific Immuno-oncology Drugs Sales and Growth Rate (K MT)
Figure 43. Asia Pacific Immuno-oncology Drugs Sales Market Share by Region in 2023
Figure 44. China Immuno-oncology Drugs Sales and Growth Rate (2019-2025) & (K MT)
Figure 45. Japan Immuno-oncology Drugs Sales and Growth Rate (2019-2025) & (K MT)
Figure 46. South Korea Immuno-oncology Drugs Sales and Growth Rate (2019-2025) & (K MT)
Figure 47. India Immuno-oncology Drugs Sales and Growth Rate (2019-2025) & (K MT)
Figure 48. Southeast Asia Immuno-oncology Drugs Sales and Growth Rate (2019-2025) & (K MT)
Figure 49. South America Immuno-oncology Drugs Sales and Growth Rate (K MT)
Figure 50. South America Immuno-oncology Drugs Sales Market Share by Country in 2023
Figure 51. Brazil Immuno-oncology Drugs Sales and Growth Rate (2019-2025) & (K MT)
Figure 52. Argentina Immuno-oncology Drugs Sales and Growth Rate (2019-2025) & (K MT)
Figure 53. Columbia Immuno-oncology Drugs Sales and Growth Rate (2019-2025) & (K MT)
Figure 54. Middle East and Africa Immuno-oncology Drugs Sales and Growth Rate (K MT)
Figure 55. Middle East and Africa Immuno-oncology Drugs Sales Market Share by Region in 2023
Figure 56. Saudi Arabia Immuno-oncology Drugs Sales and Growth Rate (2019-2025) & (K MT)
Figure 57. UAE Immuno-oncology Drugs Sales and Growth Rate (2019-2025) & (K MT)
Figure 58. Egypt Immuno-oncology Drugs Sales and Growth Rate (2019-2025) & (K MT)
Figure 59. Nigeria Immuno-oncology Drugs Sales and Growth Rate (2019-2025) & (K MT)
Figure 60. South Africa Immuno-oncology Drugs Sales and Growth Rate (2019-2025) & (K MT)
Figure 61. Global Immuno-oncology Drugs Production Market Share by Region (2019-2025)
Figure 62. North America Immuno-oncology Drugs Production (K MT) Growth Rate (2019-2025)
Figure 63. Europe Immuno-oncology Drugs Production (K MT) Growth Rate (2019-2025)
Figure 64. Japan Immuno-oncology Drugs Production (K MT) Growth Rate (2019-2025)
Figure 65. China Immuno-oncology Drugs Production (K MT) Growth Rate (2019-2025)
Figure 66. Global Immuno-oncology Drugs Sales Forecast by Volume (2019-2032) & (K MT)
Figure 67. Global Immuno-oncology Drugs Market Size Forecast by Value (2019-2032) & (M USD)
Figure 68. Global Immuno-oncology Drugs Sales Market Share Forecast by Type (2025-2032)
Figure 69. Global Immuno-oncology Drugs Market Share Forecast by Type (2025-2032)
Figure 70. Global Immuno-oncology Drugs Sales Forecast by Application (2025-2032)
Figure 71. Global Immuno-oncology Drugs Market Share Forecast by Application (2025-2032)
